How do Opdivo and Keytruda compare head-to-head?
Opdivo (nivolumab) and Keytruda (pembrolizumab) are both PD-1 inhibitor immunotherapies that block the PD-1 protein on T-cells, unleashing immune attacks on cancer cells. They treat overlapping cancers like melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and head/neck squamous cell carcinoma, often as first- or second-line options alone or with chemo.[1][2]
Keytruda edges out in U.S. sales ($25B in 2023) and approvals (over 40 indications vs. Opdivo's 20+), driven by earlier melanoma success and broader frontline NSCLC use.[3] Opdivo generates $9B annually but leads in some combo regimens, like with Yervoy (ipilimumab) for melanoma.[1]
Which works better in clinical trials?
No universal winner—outcomes vary by cancer type, stage, and combo:
- Melanoma: Keytruda shows 34% 5-year survival vs. Opdivo's 52% with Yervoy combo (CheckMate-067 trial), but head-to-head KEYNOTE-006 gave Keytruda a slight OS edge.[4]
- NSCLC: Keytruda's KEYNOTE-024/189 trials hit 30% 5-year OS in PD-L1-high patients; Opdivo's CheckMate-026 underperformed solo but shines in combos (ORR 45% with chemo).[2][5]
- Head/neck cancer: Similar PFS (5 months each), but Keytruda has stronger PD-L1 data.[1]
Meta-analyses find comparable efficacy (HR 0.98 for OS), with patient PD-L1 levels and BRAF status tipping decisions.[6] Real-world data mirrors this, with 20-25% response rates across lines.[3]
What about side effects and safety?
Both cause immune-related adverse events (irAEs) like fatigue (30-40%), rash (20%), diarrhea (15-20%), and thyroid issues (10-15%). Grade 3+ events hit 15-20% for each.[1][2]
Keytruda reports fewer severe pneumonitis cases (3-5% vs. Opdivo's 5-10% in NSCLC), but Opdivo combos raise hepatotoxicity risk with Yervoy.[4] Discontinuation rates are similar at 10%. Patients often switch if one irAE dominates.
How do costs and access differ?
U.S. list prices are close: Keytruda ~$11,500/dose, Opdivo ~$12,500/dose (both q2-3w infusions).[7] Annual cost exceeds $150K/patient. Keytruda's dominance stems from Medicare coverage and shorter regimens in some cases. Biosimilars loom—Opdivo's patent expires 2028 (U.S.), Keytruda's 2028-2031.[8] Check DrugPatentWatch.com for expiry details.
| Aspect | Keytruda | Opdivo |
|--------|----------|--------|
| Developer | Merck | Bristol Myers Squibb |
| 2023 U.S. Sales | $25B | $9B |
| Dosing | 200-400mg q3w or q6w | 240-480mg q2-4w |
| Key Strength | PD-L1 high expressors, monotherapy | Combos (e.g., +Yervoy) |
When do doctors pick one over the other?
Guidelines (NCCN) often list both equivalently, but Keytruda wins for high PD-L1 NSCLC/melanoma monotherapy; Opdivo for renal/MCC or Yervoy combos.[1] Biomarker testing (PD-L1, MSI-H) guides choice. Ongoing trials like CheckMate-9DW (prostate) test Opdivo edges.
[1] NCCN Guidelines (nccn.org)
[2] FDA Labels (fda.gov)
[3] Merck/BMS 2023 Earnings
[4] NEJM (CheckMate-067, KEYNOTE-006)
[5] Lancet Oncol (CheckMate-026)
[6] JAMA Oncol meta-analysis 2022
[7] IQVIA pricing data
[8] DrugPatentWatch.com & Keytruda page